Published On: Wed, Oct 19th, 2016

Current Price Targets For Insmed, Inc. (NASDAQ:INSM)


Recently stock market analysts have updated their consensus ratings on shares of Insmed, Inc. (NASDAQ:INSM).

Most recent broker ratings

06/09/2016 – Insmed, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 24 price target on the stock.

03/16/2016 – Insmed, Inc. had its “neutral” rating reiterated by analysts at Citigroup. They now have a USD 13 price target on the stock.

03/15/2016 – Stifel Nicolaus began new coverage on Insmed, Inc. giving the company a “buy” rating. They now have a USD 23 price target on the stock.

02/26/2016 – Insmed, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 23 price target on the stock.

11/09/2015 – Insmed, Inc. was downgraded to “neutral” by analysts at UBS. They now have a USD 18 price target on the stock.

11/09/2015 – Insmed, Inc. had its “outperform” rating reiterated by analysts at Cowen. They now have a USD 34 price target on the stock.

10/06/2015 – Insmed, Inc. had its “buy” rating reiterated by analysts at H.C. Wainwright. They now have a USD 35 price target on the stock.

05/01/2015 – Insmed, Inc. was downgraded to “hold” by analysts at Zacks.

02/09/2015 – Janney Montgomery Scott began new coverage on Insmed, Inc. giving the company a “buy” rating. They now have a USD 33 price target on the stock.

01/09/2014 – Insmed, Inc. was upgraded to “outperform” by analysts at JMP Securities. They now have a USD 25 price target on the stock.

Insmed, Inc. has a 50 day moving average of 14.18 and a 200 day moving average of 12.28. The stock’s market capitalization is 848.95M, it has a 52-week low of 9.02 and a 52-week high of 21.14.

The share price of the company (NASDAQ:INSM) was up +0.96% during the last trading session, with a high of 14.00 and the volume of Insmed, Inc. shares traded was 218702.

Insmed Incorporated is a biopharmaceutical company. The Company operates in the segment of development and commercialization of inhaled therapies for patients with serious lung diseases. The Company’s lead product candidate, ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for patients with nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. The Company’s earlier stage pipeline includes INS1009, a nebulized prodrug formulation of treprostinil, a vasodilator of pulmonary arterial vascular beds. The Company is conducting a global Phase III clinical study of ARIKAYCE (the 212 or CONVERT study) in adult patients with NTM lung disease caused by Mycobacterium avium complex (MAC), the infective species in NTM lung disease in the United States, Europe and Japan.